Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC1416 Injection in Adults With Moderate to Severe Asthma
CTR20260025Phase 2Active
- Sponsor
- Nanjing Rongjiekang
- Start
- Jan 2026
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of RC1416 in asthma, sponsored by Nanjing Rongjiekang. Started Jan 2026; status: active.
02
Drugs
RC1416
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20260025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260025.